Skip to content

Study · Non-randomized trial · n = 81 · 2022

11 results

Clinical effect of Xuebijing combined with thymosinα1 on patients with severe pneumonia complicated with sepsis and its effect on serum inflammatory factors.

Chen Y, Zhou L, Wang J, Gu T, Li S

Cellular and molecular biology (Noisy-le-Grand, France)27 Feb 2022Cited by 7 (Europe PMC)

PMID35818192 (opens in a new tab)DOI10.14715/cmb/2021.67.6.30 (opens in a new tab)PepBankPUB-35818192
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave lower body temperature after treatment than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower body temperature than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBody temperature after treatment
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Results showed that after treatment, the body temperature, respiration, heart rate, leukocytes and other general conditions of the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave a lower respiration rate after treatment than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to a lower breathing rate than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRespiration after treatment
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Results showed that after treatment, the body temperature, respiration, heart rate, leukocytes and other general conditions of the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave a lower heart rate after treatment than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to a lower heart rate than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHeart rate after treatment
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Results showed that after treatment, the body temperature, respiration, heart rate, leukocytes and other general conditions of the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave lower leukocyte counts after treatment than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower white blood cell counts than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLeukocytes after treatment
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Results showed that after treatment, the body temperature, respiration, heart rate, leukocytes and other general conditions of the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave a lower blood pH than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to a lower blood pH than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBlood gas index pH
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The blood gas indexes pH and PaCO2 levels of the study group were lower than those of the control group.
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave a lower PaCO2 than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower blood carbon dioxide than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBlood gas index PaCO2
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The blood gas indexes pH and PaCO2 levels of the study group were lower than those of the control group.
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave lower serum IL-6 than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower IL-6, an inflammation marker, than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum IL-6
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The levels of serum interleukin-6 (IL-6), serum tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave lower serum TNF-α than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower TNF-α, an inflammation marker, than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum TNF-α
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The levels of serum interleukin-6 (IL-6), serum tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave lower serum CRP than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing was linked to lower CRP, an inflammation marker, than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum C-reactive protein
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The levels of serum interleukin-6 (IL-6), serum tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, the abstract reports a lower bacterial clearance rate with added thymosin alpha‑1 than with Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, the bacterial clearance rate was reported as lower with thymosin alpha‑1 plus Xuebijing than with Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBacterial clearance rate
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The bacterial clearance rate of the study group was lower than that of the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with severe pneumonia and sepsis given Xuebijing, adding thymosin alpha‑1 gave a higher total effective rate than Xuebijing alone.

    In plain wordsIn patients with severe pneumonia and sepsis, adding thymosin alpha‑1 to Xuebijing gave a higher treatment effective rate than Xuebijing alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTotal effective rate of treatment
    Study

    n = 81

    Comparator
    Xuebijing injection alone
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The total effective rate of treatment of patients in the study group was higher than that of patients in the control group (all p<0.05).
    2 context sentences
    Summary · context
    41 cases who received Xuebijing injection by intravenous drip were selected as the control group.
    Summary · context
    40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.